Browsing Tag
amivantamab
3 posts
Dizal’s sunvozertinib beats chemo in phase 3 first-line NSCLC trial, opening path to new drug applications
Dizal's sunvozertinib beats platinum chemo in WU-KONG28 phase 3 first-line EGFR exon 20 NSCLC trial. What this means for patients, rivals and investors. Read more.
Johnson & Johnson strengthens oncology delivery strategy with EU nod for subcutaneous amivantamab
EU approves subcutaneous amivantamab for EGFR lung cancer. Discover how this could reshape oncology workflows and Johnson & Johnson’s strategy.
Johnson & Johnson’s RYBREVANT approved by FDA as second-line option for EGFR-mutated NSCL
The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson’s RYBREVANT (amivantamab-vmjw) in combination with chemotherapy…